Navigation Links
Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
Date:1/8/2008

>

Nastech is a biopharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech is creating technologies that enable the delivery of peptide and protein therapeutics without the requirement of an injection, which is currently the most common form of administration for this class of drugs. Nastech has also established a wholly-owned subsidiary, MDRNA, Inc., to focus on developing RNA-based technologies and therapeutics. MDRNA is harnessing the power of RNA interference, a cellular mechanism that can turn off the production of a specific protein through use of small interfering RNAs (siRNAs), to develop a new class of therapeutics by identifying key protein targets, designing the siRNAs that will turn off the production of the targeted proteins, and creating a formulation for the delivery of the therapeutics. Nastech and its collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. For additional information about Nastech please visit http://www.nastech.com.

Nastech Forward Looking Statements

Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech or a subsidiary to obtain additional funding; (ii) the ability of Nastech or a subsidiary to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Nastech, a subsidiary and/or a partner to successfully complete product research and dev
'/>"/>

SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
2. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
3. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Boston Children,s Hospital,s Global Pediatric Summit + Awards, ... "Innovation Tank" – a forum designed to give pediatric ... or product solution to a panel of acclaimed judges ... accelerate the innovation and bring it to market. ... 31, will be moderated by Daymond John ...
(Date:7/24/2014)... 24, 2014  Bruin Biometrics (BBI), a pioneer ... after two weeks of clinical briefings to over ... it gained substantial concurrence on both the clinical ... utility of BBI,s SEM Scanner. ... the respondents drawn from the European Wound Management ...
(Date:7/24/2014)... N.J. , July 24, 2014  Bayer ... III trial that evaluated a 15% foam formulation ... topical treatment of inflammatory papules and pustules of ... treatment option to complement the currently available AzA ... causing inflammatory lesions (papules and pustules) as well ...
Breaking Medicine Technology:Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 2Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 3Bruin Biometrics Secures Support of EU Scientific Community for its SEM Scanner Technology 2Phase III Investigational Trial of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints in Subjects with Papulopustular Rosacea 2Phase III Investigational Trial of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints in Subjects with Papulopustular Rosacea 3
... The Leukemia & Lymphoma,Society has awarded a $550,000 ... Wilmot Cancer Center at the University of Rochester Medical,Center. ... funding the first two years of the five-year program., ... will support,Dr. Friedberg,s work on a new targeted treatment ...
... Assay Submitted for FDA Clearance, SAN DIEGO, July ... and Company) (NYSE: BDX ), announced today the ... the rapid diagnosis,of patients with Clostridium difficile infection (CDI). ... simplicity and speed in one test,procedure. BD has also ...
Cached Medicine Technology:University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society 2BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections 2BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections 3
(Date:7/24/2014)... 2014 Indianapolis* VxP Pharma Services ... offering to include process development and commercial ... dosage forms offered by VxP now include:, ... Liquids ,     Sterile Liquids and Sterile ...     Topicals ,     Transdermal Patches , ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Dr. Peter ... Israel Deaconess Medical Center in Boston, is the new ... Dr. Oettgen brings his considerable experience in the field ... Health . , Dr. Oettgen received his medical ... and completed his residency at Tufts New England Medical ...
(Date:7/24/2014)... Texas (PRWEB) July 24, 2014 ... provides key market data on the North America ... millions of US dollars, and volume (in units) ... market categories Spinal Fusion, Vertebral Compression Fracture Repair ... Companies in North America Spinal Surgery Market:, ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The European air ... billion in 2014, and is expected to register a CAGR ... France, Germany, Russia, and turkey are the major spenders in ... include medium extended air defense program and multinational (MEADS) program, ... , Browse through the TOC of the Europe air and ...
(Date:7/24/2014)... cancer involves exposing the patient or their tumor more ... X-rays. The radiation damages the cancer cells irreparably. Unfortunately, ... the skin over the site of the tumor, which ... and even skin cancer. As such finding ways to ... in the International Journal of Low Radiation, Faruck Lukmanul ...
Breaking Medicine News(10 mins):Health News:VxP Pharma Expands Commercial Service Offering 2Health News:DynaMed™ Names Peter Oettgen, MD as Deputy Editor of Cardiology 2Health News:DynaMed™ Names Peter Oettgen, MD as Deputy Editor of Cardiology 3Health News:Spinal Surgery Market in North America Forecast to 2020 New Report Available at ReportsnReports.com 2Health News:Spinal Surgery Market in North America Forecast to 2020 New Report Available at ReportsnReports.com 3Health News:Spinal Surgery Market in North America Forecast to 2020 New Report Available at ReportsnReports.com 4Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 2Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 3Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 4Health News:Natural products from plants protect skin during cancer radiotherapy 2
... , , , EAST HARTFORD, Conn., Aug. 6 ... Thursday morning August 6 due to a denial of service attack. , , ... , - Why are Web 2.0 sites like Twitter targets for ... brain than a simple website. Its users are within the brain and its neurons, ...
... , , MOUNTAIN VIEW, Calif., Aug. 6 ... will release its second quarter 2009 financial results after the market closes ... with the release, the Company will host a conference call with the ... Thursday, August 13, 2009 to discuss the results ...
... problems , THURSDAY, Aug. 6 (HealthDay News) -- Rooks aren,t birdbrains, ... the corvid, or crow, family can use stones to raise the ... within reach of their beak. , All four rooks used in ... exact number of stones needed to raise the water level to ...
... , National Psoriasis Foundation data show ... , , PORTLAND, Ore., Aug. 6 Emerging research ... medical conditions including heart disease, diabetes and obesity. According to a new ... two-thirds report having at least one other critical health problem , ...
... NEW YORK, Aug. 6 Care to Care, a ... that is has been awarded Full Accreditation in Health Utilization ... care accrediting organization. , , URAC ... care management through processes of accreditation and education. URAC ...
... , , WASHINGTON, Aug. ... non-profit organization of nearly 60 employer-based health care coalitions, representing ... dependents across the United States, submitted letters to the White ... as a critical strategy for health reform. NBCH sent correspondence ...
Cached Medicine News:Health News:Integralis Expert Resource Available to Discuss Twitter Denial of Service Attack and Web 2.0 Security 2Health News:Rooks Show Intelligence in Catching the Worm 2Health News:Largest Survey of Its Kind Finds That People With Psoriasis Are at Risk for Other Medical Conditions 2Health News:Largest Survey of Its Kind Finds That People With Psoriasis Are at Risk for Other Medical Conditions 3Health News:Care to Care Receives Full URAC Health Utilization Management Accreditation 2Health News:Care to Care Receives Full URAC Health Utilization Management Accreditation 3Health News:NBCH Calls for Cost Containment and System Transformation in Health Care Reform Legislation 2Health News:NBCH Calls for Cost Containment and System Transformation in Health Care Reform Legislation 3
Ideal for use with thinner casting materials such as polyester or fiberglass. Conforms to any casting material....
This lightweight cast boot features a sturdy canvas upper. The three layer EVA rocker outsole provides excellent shock absorption....
... assay for the qualitative and ... to Gliadin in human serum. ... be used as an aid ... disorders, mainly Coeliac Disease. This ...
... Myeloperoxidase IgG ELISA test system is intended ... IgG-class antibody to myeloperoxidase in human serum. ... used as an aid in the diagnosis ... elevated levels of anti-neutrophil cytoplasmic antibodies (ANCA). ...
Medicine Products: